ES2979379T3 - Procedimiento para la preparación de compuesto de triaminopirimidina y productos intermedios del mismo - Google Patents

Procedimiento para la preparación de compuesto de triaminopirimidina y productos intermedios del mismo Download PDF

Info

Publication number
ES2979379T3
ES2979379T3 ES18778565T ES18778565T ES2979379T3 ES 2979379 T3 ES2979379 T3 ES 2979379T3 ES 18778565 T ES18778565 T ES 18778565T ES 18778565 T ES18778565 T ES 18778565T ES 2979379 T3 ES2979379 T3 ES 2979379T3
Authority
ES
Spain
Prior art keywords
compound
triaminopyrimidine
crystalline form
solvents
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18778565T
Other languages
English (en)
Spanish (es)
Inventor
Kumar Kamlesh Singh
Nikhil Amar Singh
Ganapatdan Shimbhu Charan
Nimeshkumar Mukeshkumar Shah
Sunil Dnyaneshwar Narode
Dipakkumar Dhanjibhai Vachhani
Amol Kashinath Patil
Sandip Pundlik Khairnar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zydus Lifesciences Ltd
Original Assignee
Zydus Lifesciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zydus Lifesciences Ltd filed Critical Zydus Lifesciences Ltd
Application granted granted Critical
Publication of ES2979379T3 publication Critical patent/ES2979379T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES18778565T 2017-09-05 2018-09-04 Procedimiento para la preparación de compuesto de triaminopirimidina y productos intermedios del mismo Active ES2979379T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201721031453 2017-09-05
IN201721034342 2017-09-27
PCT/IB2018/056732 WO2019049021A1 (en) 2017-09-05 2018-09-04 PROCESS FOR THE PREPARATION OF TRIAMINOPYRIMIDINE COMPOUND AND ITS INTERMEDIATES

Publications (1)

Publication Number Publication Date
ES2979379T3 true ES2979379T3 (es) 2024-09-25

Family

ID=63684213

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18778565T Active ES2979379T3 (es) 2017-09-05 2018-09-04 Procedimiento para la preparación de compuesto de triaminopirimidina y productos intermedios del mismo

Country Status (10)

Country Link
US (1) US12378223B2 (enExample)
EP (1) EP3679030B1 (enExample)
JP (1) JP2020532513A (enExample)
CN (1) CN111051299A (enExample)
CA (1) CA3071226A1 (enExample)
ES (1) ES2979379T3 (enExample)
MX (2) MX2020002142A (enExample)
PH (1) PH12020500385A1 (enExample)
WO (1) WO2019049021A1 (enExample)
ZA (1) ZA202000903B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025115034A1 (en) * 2023-11-30 2025-06-05 Zydus Lifesciences Limited A process for the preparation of a triaminopyrimidine compound and novel intermediates thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58124B1 (sr) * 2014-04-28 2019-02-28 Medicines For Malaria Venture Mmv Triaminopirimidin jedinjenja korisna za prevenciju ili tretman malarije

Also Published As

Publication number Publication date
ZA202000903B (en) 2024-07-31
EP3679030B1 (en) 2024-03-27
US12378223B2 (en) 2025-08-05
EP3679030A1 (en) 2020-07-15
JP2020532513A (ja) 2020-11-12
MX2024002113A (es) 2024-03-06
PH12020500385A1 (en) 2020-12-07
CN111051299A (zh) 2020-04-21
US20200207738A1 (en) 2020-07-02
CA3071226A1 (en) 2019-03-14
BR112020003557A2 (pt) 2020-09-01
WO2019049021A1 (en) 2019-03-14
MX2020002142A (es) 2020-07-20

Similar Documents

Publication Publication Date Title
ES2389565T3 (es) Rosuvastatina y sales de la misma carentes de alquiléter de rosuvatatina y un procedimiento para la preparación de las mismas
CA2958139A1 (en) Solid state forms of ibrutinib
EP3209652B1 (en) Tricyclic atropisomer compounds
CN104736540B (zh) 培美曲塞及其赖氨酸盐的制备方法
JP6374436B2 (ja) 純粋なエルロチニブ
ES2879294T3 (es) Formas polimórficas de Belinostat y procesos para la preparación de las mismas
US10144708B2 (en) Crystalline arylalkylamine compound and process for producing the same
CN109384767B (zh) 一种吡啶并嘧啶类衍生物的制备方法及其中间体
CA2996258A1 (en) A process for the preparation of xylene linked cyclam compounds
KR100878698B1 (ko) 결정형의 베포타스틴 금속염 수화물, 이의 제조방법 및이를 포함하는 약학 조성물
US20180057503A1 (en) Pharmaceutically Acceptable Salts and Polymorphic Forms of Hydrocodone Benzoic Acid Enol Ester and Processes for Making Same
EP3679030B1 (en) A process for preparation of triaminopyrimidine compound and intermediates thereof
EP2414317A2 (en) Palladium-catalyzed ortho-fluorination
WO2020053795A2 (en) Process for the preparation of acalabrutinib and its intermediates
BR112020003557B1 (pt) Formas cristalinas de um composto de triaminopirimidina, processos para a preparação do referido composto, composto de triaminopirimidina apresentando as referidas formas cristalinas e composições compreendendo o referido composto
KR102793047B1 (ko) 4-치환 옥사졸로퀴놀리논 유도체, 약학적으로 허용되는 이의 염인 화합물 및 이를 유효성분으로 포함하는 천식 또는 아토피 등의 알러지성 질환의 예방 또는 치료용 약학 조성물
CN114195800A (zh) Usp7抑制剂
US9796677B2 (en) Amide compound and pharmaceutical comprising same
KR101307712B1 (ko) 결정형의 베포타스틴 금속염 수화물, 이의 제조방법 및 이를 포함하는 약학 조성물
KR20200029751A (ko) 보티옥세틴 니코티네이트 및 이의 제조방법
KR20190039087A (ko) 정제된 세니크리비록 및 세니크리비록을 제조하기 위한 정제된 중간체
KR20160065496A (ko) 페녹시피리미디논 유사체의 재결정을 통한 정제 방법
KR20200068667A (ko) 고체 형태의 스테모스피로닌 및 이의 염
KR100267059B1 (ko) 3-비닐퀴놀린 유도체 및 약학적으로 허용되는 그의 염
TW202408515A (zh) 含有kras g12c抑制劑及奧諾拉(aurora)a抑制劑之治療方法